Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 7/2013

01.07.2013 | Review

Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance

verfasst von: E. Montassier, E. Batard, T. Gastinne, G. Potel, M. F. de La Cochetière

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 7/2013

Einloggen, um Zugang zu erhalten

Abstract

Bacteremia remains a major cause of life-threatening complication in patients with cancer. Significant changes in the spectrum of microorganisms isolated from blood culture have been reported in cancer patients over the past years. The aim of our systematic review was to inventory the recent trends in epidemiology and antibiotic resistance of microorganisms causing bacteremia in cancer patients. Data for this review was identified by searches of Medline, Scopus and Cochrane Library for indexed articles and abstracts published in English since 2008. The principal search terms were: “antimicrobial resistance”, “bacteremia”, “bacterial epidemiology”, “bloodstream infection”, “cancer patients”, “carbapenem resistance”, “Escherichia coli resistance”, “extended-spectrum β-lactamase producing E. coli”, “febrile neutropenia”, “fluoroquinolone resistance”, “neutropenic cancer patient”, “vancomycin-resistant Enterococcus”, and “multidrug resistance”. Boolean operators (NOT, AND, OR) were also used in succession to narrow and widen the search. Altogether, 27 articles were selected to be analyzed in the review. We found that Gram-negative bacteria were the most frequent pathogen isolated, particularly in studies with minimal use of antibiotic prophylaxis. Another important trend is the extensive emergence of antimicrobial-resistant strains associated with increased risk of morbidity, mortality and cost. This increasing incidence of antibiotic resistance has been reported in Gram-negative bacteria as well as in Gram-positive bacteria. This exhaustive review, reporting the recent findings in epidemiology and antibiotic resistance of bacteremia in cancer patients, highlights the necessity of local continuous surveillance of bacteremia and stringent enforcement of antibiotic stewardship programs in cancer patients.
Literatur
1.
Zurück zum Zitat Klastersky J (2004) Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 39:S327CrossRef Klastersky J (2004) Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 39:S327CrossRef
2.
Zurück zum Zitat Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):427–431CrossRefPubMed Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):427–431CrossRefPubMed
3.
Zurück zum Zitat Arnold RJ, Gabrail N, Rat M, Kim R, Sung JC, Zhou Y (2005) Clinical implications of chemotherapy induced diarrhea in patients with cancer. J Support Oncol 3:227–232PubMed Arnold RJ, Gabrail N, Rat M, Kim R, Sung JC, Zhou Y (2005) Clinical implications of chemotherapy induced diarrhea in patients with cancer. J Support Oncol 3:227–232PubMed
4.
Zurück zum Zitat van Vliet MJ, Harmsen HJ, de Bont ES, Tissing WJ (2010) The role of intestinal microbiota in the development and severity of chemotherapy-induced Mucositis. Plos Pathol 27:e1000879CrossRef van Vliet MJ, Harmsen HJ, de Bont ES, Tissing WJ (2010) The role of intestinal microbiota in the development and severity of chemotherapy-induced Mucositis. Plos Pathol 27:e1000879CrossRef
5.
Zurück zum Zitat Jones RN (1999) Contemporary antimicrobial susceptibility pattern of bacterial pathogens commonly associated with febrile patients with neutropenia. Clin Infect Dis 29:495–502CrossRefPubMed Jones RN (1999) Contemporary antimicrobial susceptibility pattern of bacterial pathogens commonly associated with febrile patients with neutropenia. Clin Infect Dis 29:495–502CrossRefPubMed
6.
Zurück zum Zitat Irfan S, Idrees F, Mehraj V, Habib F, Adil S, Hasan R (2008) Emergence of Carbapenem resistant Gram negative and vancomycin resistant Gram positive organisms in bacteremic isolates of febrile neutropenic patients: a descriptive study. BMC Infect Dis 8:80CrossRefPubMed Irfan S, Idrees F, Mehraj V, Habib F, Adil S, Hasan R (2008) Emergence of Carbapenem resistant Gram negative and vancomycin resistant Gram positive organisms in bacteremic isolates of febrile neutropenic patients: a descriptive study. BMC Infect Dis 8:80CrossRefPubMed
7.
Zurück zum Zitat Ramphal R (2004) Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 39:S25–S31CrossRefPubMed Ramphal R (2004) Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 39:S25–S31CrossRefPubMed
8.
Zurück zum Zitat Zinner SH (1999) Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 29:490–494CrossRefPubMed Zinner SH (1999) Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 29:490–494CrossRefPubMed
9.
Zurück zum Zitat Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB (2003) Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 36:1103–1110CrossRefPubMed Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB (2003) Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 36:1103–1110CrossRefPubMed
10.
Zurück zum Zitat Sharma A, Lokeshwar N (2005) Febrile neutropenia in haematological malignancies. J Postgrad Med 51:42–48 Sharma A, Lokeshwar N (2005) Febrile neutropenia in haematological malignancies. J Postgrad Med 51:42–48
11.
Zurück zum Zitat Wu HS, Kuo SC, Lee YT, Yang YS, Cheng SS, Chen TL, Fung CP (2012) Clinical characteristics and prognostic factors of Acinetobacter nosocomialis bacteraemia in patients with solid tumours. Clin Microbiol Infect 18(9):E373–E376CrossRefPubMed Wu HS, Kuo SC, Lee YT, Yang YS, Cheng SS, Chen TL, Fung CP (2012) Clinical characteristics and prognostic factors of Acinetobacter nosocomialis bacteraemia in patients with solid tumours. Clin Microbiol Infect 18(9):E373–E376CrossRefPubMed
12.
Zurück zum Zitat Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW (2004) Bloodstream infections due to extended spectrum factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 48:4574–4581CrossRefPubMed Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW (2004) Bloodstream infections due to extended spectrum factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 48:4574–4581CrossRefPubMed
13.
Zurück zum Zitat Kim YK, Pai H, Lee HJ, Park SE, Choi EH, Kim J, Kim JH, Kim EC (2002) Bloodstream infections by extended-spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 46(1481):1491 Kim YK, Pai H, Lee HJ, Park SE, Choi EH, Kim J, Kim JH, Kim EC (2002) Bloodstream infections by extended-spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 46(1481):1491
14.
Zurück zum Zitat Cattaneo C, Antoniazzi F, Casari S, Ravizzola G, Gelmi M, Pagani C, D’Adda M, Morello E, Re A, Borlenghi E, Manca N, Rossi G (2012) P. aeruginosa bloodstream infections among hematological patients: an old or new question? Ann Hematol 91(8):1299–1304CrossRefPubMed Cattaneo C, Antoniazzi F, Casari S, Ravizzola G, Gelmi M, Pagani C, D’Adda M, Morello E, Re A, Borlenghi E, Manca N, Rossi G (2012) P. aeruginosa bloodstream infections among hematological patients: an old or new question? Ann Hematol 91(8):1299–1304CrossRefPubMed
15.
Zurück zum Zitat Kjellander C, Björkholm M, Cherif H, Kalin M, Giske CG (2012) Hematological: low all-cause mortality and low occurrence of antimicrobial resistance in hematological patients with bacteremia receiving no antibacterial prophylaxis: a single-center study. Eur J Haematol 88(5):422–430CrossRefPubMed Kjellander C, Björkholm M, Cherif H, Kalin M, Giske CG (2012) Hematological: low all-cause mortality and low occurrence of antimicrobial resistance in hematological patients with bacteremia receiving no antibacterial prophylaxis: a single-center study. Eur J Haematol 88(5):422–430CrossRefPubMed
16.
Zurück zum Zitat Chong Y, Yakushiji H, Ito Y, Kamimura T (2011) Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies. Int J Infect Dis 15(4):e277–e281CrossRefPubMed Chong Y, Yakushiji H, Ito Y, Kamimura T (2011) Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies. Int J Infect Dis 15(4):e277–e281CrossRefPubMed
17.
Zurück zum Zitat Saghir S, Faiz M, Saleem M, Younus A, Aziz H (2009) Characterization and anti-microbial susceptibility of Gram-negative bacteria isolated from bloodstream infections of cancer patients on chemotherapy in Pakistan. Indian J Med 27:341–347 Saghir S, Faiz M, Saleem M, Younus A, Aziz H (2009) Characterization and anti-microbial susceptibility of Gram-negative bacteria isolated from bloodstream infections of cancer patients on chemotherapy in Pakistan. Indian J Med 27:341–347
18.
Zurück zum Zitat Kang CI, Song JH, Chung DR, Peck KR, Yeom JS, Son JS, Wi YM, on behalf of the Korean Network for Study on Infectious Diseases (KONSID) (2012) Bloodstream infections in adult patients with cancer: clinical features and pathogenic significance of Staphylococcus aureus bacteremia. Support Care Cancer 20(10):2371–2378 Kang CI, Song JH, Chung DR, Peck KR, Yeom JS, Son JS, Wi YM, on behalf of the Korean Network for Study on Infectious Diseases (KONSID) (2012) Bloodstream infections in adult patients with cancer: clinical features and pathogenic significance of Staphylococcus aureus bacteremia. Support Care Cancer 20(10):2371–2378
19.
Zurück zum Zitat Lanoix JP, Pluquet E, Lescure FX, Bentayeb H, Lecuyer E, Boutemy M, Dumont P, Jounieaux V, Schmit JL, Dayen C, Douadi Y (2011) Bacterial infection profiles in lung cancer patients with febrile neutropenia. BMC Infect Dis 11:183CrossRefPubMed Lanoix JP, Pluquet E, Lescure FX, Bentayeb H, Lecuyer E, Boutemy M, Dumont P, Jounieaux V, Schmit JL, Dayen C, Douadi Y (2011) Bacterial infection profiles in lung cancer patients with febrile neutropenia. BMC Infect Dis 11:183CrossRefPubMed
20.
Zurück zum Zitat Gudiol C, Bodro M, Simonetti A, Tubau F, González-Barca E, Cisnal M, Domingo-Domenech E, Jiménez L, Carratalà J (2012) Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect. doi:10.1111/j.1469-0691.2012.03879 Gudiol C, Bodro M, Simonetti A, Tubau F, González-Barca E, Cisnal M, Domingo-Domenech E, Jiménez L, Carratalà J (2012) Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect. doi:10.​1111/​j.​1469-0691.​2012.​03879
21.
Zurück zum Zitat Trecarichi EM, Tumbarello M, Spanu T, Caira M, Fianchi L, Chiusolo P, Fadda G, Leone G, Cauda R, Pagano L (2009) Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect 58(4):299–307CrossRefPubMed Trecarichi EM, Tumbarello M, Spanu T, Caira M, Fianchi L, Chiusolo P, Fadda G, Leone G, Cauda R, Pagano L (2009) Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect 58(4):299–307CrossRefPubMed
22.
Zurück zum Zitat Bhusal Y, Mihu CN, Tarrand JJ, Rolston KV (2011) Incidence of fluoroquinolone-resistant and extended-spectrum β-lactamase-producing Escherichia coli at a comprehensive cancer center in the United States. Chemotherapy 57(4):335–338CrossRefPubMed Bhusal Y, Mihu CN, Tarrand JJ, Rolston KV (2011) Incidence of fluoroquinolone-resistant and extended-spectrum β-lactamase-producing Escherichia coli at a comprehensive cancer center in the United States. Chemotherapy 57(4):335–338CrossRefPubMed
23.
Zurück zum Zitat Jacobson K, Rolston K, Elting L, LeBlanc B, Whimbey E, Ho DH (1999) Susceptibility surveillance among Gram-negative bacilli at a cancer center. Chemotherapy 45:325–334CrossRefPubMed Jacobson K, Rolston K, Elting L, LeBlanc B, Whimbey E, Ho DH (1999) Susceptibility surveillance among Gram-negative bacilli at a cancer center. Chemotherapy 45:325–334CrossRefPubMed
24.
Zurück zum Zitat Mihu CN, Rhomberg PR, Jones RN, Coyle E, Prince RA, Rolston KV (2010) Escherichia coli resistance to quinolones at a comprehensive cancer center. Diagn Microbiol Infect Dis 67(3):266–269CrossRefPubMed Mihu CN, Rhomberg PR, Jones RN, Coyle E, Prince RA, Rolston KV (2010) Escherichia coli resistance to quinolones at a comprehensive cancer center. Diagn Microbiol Infect Dis 67(3):266–269CrossRefPubMed
25.
Zurück zum Zitat Bell JM, Turnidge JD, Gales AC, Pfaller MA, Jones RN, Sentry APAC Study Group (2002) Prevalence of extended-spectrum beta-lactamase (ESBL)—producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998–99). Diagn Microbiol Infect Dis 42:193–198CrossRefPubMed Bell JM, Turnidge JD, Gales AC, Pfaller MA, Jones RN, Sentry APAC Study Group (2002) Prevalence of extended-spectrum beta-lactamase (ESBL)—producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998–99). Diagn Microbiol Infect Dis 42:193–198CrossRefPubMed
26.
Zurück zum Zitat Gulay Z, Thomson CJ, Yulug N, Amyes SG (2000) High prevalence of extended spectrum beta-lactamase production among Klebsiella pneumoniae strains isolated at a university hospital in Turkey. J Chemother 12:145–152PubMed Gulay Z, Thomson CJ, Yulug N, Amyes SG (2000) High prevalence of extended spectrum beta-lactamase production among Klebsiella pneumoniae strains isolated at a university hospital in Turkey. J Chemother 12:145–152PubMed
27.
Zurück zum Zitat Vahaboglu H, Ozturk R, Aygun G, Coşkunkan F, Yaman A, Kaygusuz A, Leblebicioglu H, Balik I, Aydin K, Otkun M (1997) Widespread detection of PER-1–type extended-spectrum beta-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob Agents Chemother 41:2265–2269PubMed Vahaboglu H, Ozturk R, Aygun G, Coşkunkan F, Yaman A, Kaygusuz A, Leblebicioglu H, Balik I, Aydin K, Otkun M (1997) Widespread detection of PER-1–type extended-spectrum beta-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob Agents Chemother 41:2265–2269PubMed
28.
Zurück zum Zitat Arnan M, Gudiol C, Calatayud L, Liñares J, Dominguez MA, Batlle M, Ribera JM, Carratalà J, Gudiol F (2011) Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. Eur J Clin Microbiol Infect Dis 30(3):355–360CrossRefPubMed Arnan M, Gudiol C, Calatayud L, Liñares J, Dominguez MA, Batlle M, Ribera JM, Carratalà J, Gudiol F (2011) Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. Eur J Clin Microbiol Infect Dis 30(3):355–360CrossRefPubMed
29.
Zurück zum Zitat Gudiol C, Calatayud L, Garcia-Vidal C, Lora-Tamayo J, Cisnal M, Duarte R, Arnan M, Marin M, Carratalà J, Gudiol F (2010) Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother 65(2):333–341CrossRefPubMed Gudiol C, Calatayud L, Garcia-Vidal C, Lora-Tamayo J, Cisnal M, Duarte R, Arnan M, Marin M, Carratalà J, Gudiol F (2010) Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother 65(2):333–341CrossRefPubMed
30.
Zurück zum Zitat Liss BJ, Vehreschild JJ, Cornely OA, Hallek M, Fätkenheuer G, Wisplinghoff H, Seifert H, Vehreschild MJ (2012) Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection 40(6):613–619CrossRefPubMed Liss BJ, Vehreschild JJ, Cornely OA, Hallek M, Fätkenheuer G, Wisplinghoff H, Seifert H, Vehreschild MJ (2012) Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection 40(6):613–619CrossRefPubMed
31.
Zurück zum Zitat Kang CI, Chung DR, Ko KS, Peck KR, Song JH, Korean Network for Study of Infectious Diseases (2012) Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Ann Hematol 91(1):115–121CrossRefPubMed Kang CI, Chung DR, Ko KS, Peck KR, Song JH, Korean Network for Study of Infectious Diseases (2012) Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Ann Hematol 91(1):115–121CrossRefPubMed
32.
Zurück zum Zitat Almyroudis NG, Fuller A, Jakubowski A, Sepkowitz K, Jaffe D, Small TN, Kiehn TE, Pamer E, Papanicolaou GA (2005) Pre- and postengraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis 7:11–17CrossRefPubMed Almyroudis NG, Fuller A, Jakubowski A, Sepkowitz K, Jaffe D, Small TN, Kiehn TE, Pamer E, Papanicolaou GA (2005) Pre- and postengraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis 7:11–17CrossRefPubMed
33.
Zurück zum Zitat Avery R, Kalaycio M, Pohlman B, Sobecks R, Kuczkowski E, Andresen S, Mossad S, Shamp J, Curtis J, Kosar J, Sands K, Serafin M, Bolwell B (2005) Early vancomycin resistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course. Bone Marrow Transplant 35:497–499CrossRefPubMed Avery R, Kalaycio M, Pohlman B, Sobecks R, Kuczkowski E, Andresen S, Mossad S, Shamp J, Curtis J, Kosar J, Sands K, Serafin M, Bolwell B (2005) Early vancomycin resistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course. Bone Marrow Transplant 35:497–499CrossRefPubMed
34.
Zurück zum Zitat Kapur D, Dorsky D, Feingold JM, Bona RD, Edwards RL, Aslanzadeh J, Tutschka PJ, Bilgrami S (2000) Incidence and outcome of vancomycin-resistant enterococcal bacteremia following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 25:147–152CrossRefPubMed Kapur D, Dorsky D, Feingold JM, Bona RD, Edwards RL, Aslanzadeh J, Tutschka PJ, Bilgrami S (2000) Incidence and outcome of vancomycin-resistant enterococcal bacteremia following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 25:147–152CrossRefPubMed
35.
Zurück zum Zitat Weinstock DM, Conlon M, Iovino C, Aubrey T, Gudiol C, Riedel E, Young JW, Kiehn TE, Zuccotti G (2007) Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant 13:615–621CrossRefPubMed Weinstock DM, Conlon M, Iovino C, Aubrey T, Gudiol C, Riedel E, Young JW, Kiehn TE, Zuccotti G (2007) Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant 13:615–621CrossRefPubMed
36.
Zurück zum Zitat Zirakzadeh A, Gastineau DA, Mandrekar JN, Burke JP, Johnston BP, Patel R (2008) Vancomycin-resistant enterococcal colonization appears associated with increased mortality among allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 41:385–392CrossRefPubMed Zirakzadeh A, Gastineau DA, Mandrekar JN, Burke JP, Johnston BP, Patel R (2008) Vancomycin-resistant enterococcal colonization appears associated with increased mortality among allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 41:385–392CrossRefPubMed
37.
Zurück zum Zitat Kamboj M, Chung D, Seo SK, Pamer EG, Sepkowitz KA, Jakubowski AA, Papanicolaou G (2010) The changing epidemiology of vancomycin-resistant Enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Biol Blood Marrow Transplant 16(11):1576–1581CrossRefPubMed Kamboj M, Chung D, Seo SK, Pamer EG, Sepkowitz KA, Jakubowski AA, Papanicolaou G (2010) The changing epidemiology of vancomycin-resistant Enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Biol Blood Marrow Transplant 16(11):1576–1581CrossRefPubMed
38.
Zurück zum Zitat Bossaer JB, Hall PD, Garrett-Mayer E (2010) Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE. Support Care Cancer 19(2):231–237CrossRefPubMed Bossaer JB, Hall PD, Garrett-Mayer E (2010) Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE. Support Care Cancer 19(2):231–237CrossRefPubMed
39.
Zurück zum Zitat Quilty S, Kwok G, Hajkowicz K, Currie B (2009) High incidence of methicillin resistant Staphylococcus aureus sepsis and death in patients with febrile neutropenia at Royal Darwin Hospital. Intern Med J 39:557–559CrossRefPubMed Quilty S, Kwok G, Hajkowicz K, Currie B (2009) High incidence of methicillin resistant Staphylococcus aureus sepsis and death in patients with febrile neutropenia at Royal Darwin Hospital. Intern Med J 39:557–559CrossRefPubMed
40.
Zurück zum Zitat Prabhash K, Medhekar A, Ghadyalpatil N, Noronha V, Biswas S, Kurkure P, Nair R, Kelkar R (2010) Blood stream infections in cancer patients: a single center experience of isolates and sensitivity pattern. Indian J Cancer 47:184–188CrossRefPubMed Prabhash K, Medhekar A, Ghadyalpatil N, Noronha V, Biswas S, Kurkure P, Nair R, Kelkar R (2010) Blood stream infections in cancer patients: a single center experience of isolates and sensitivity pattern. Indian J Cancer 47:184–188CrossRefPubMed
41.
Zurück zum Zitat Karim M, Khan W, Farooqi B, Malik I (1991) Bacterial isolates in neutropenic febrile patients. J Pak Med Assoc 48:364–367 Karim M, Khan W, Farooqi B, Malik I (1991) Bacterial isolates in neutropenic febrile patients. J Pak Med Assoc 48:364–367
42.
Zurück zum Zitat Rangaraj G, Granwehr BP, Jiang Y, Hachem R, Raad I (2010) Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms. Cancer 116(4):967–973CrossRefPubMed Rangaraj G, Granwehr BP, Jiang Y, Hachem R, Raad I (2010) Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms. Cancer 116(4):967–973CrossRefPubMed
43.
Zurück zum Zitat Gudiol C, Tubau F, Calatayud L, Garcia-Vidal C, Cisnal M, Sánchez-Ortega I, Duarte R, Calvo M, Carratalà J (2011) Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother 66(3):657–663CrossRefPubMed Gudiol C, Tubau F, Calatayud L, Garcia-Vidal C, Cisnal M, Sánchez-Ortega I, Duarte R, Calvo M, Carratalà J (2011) Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother 66(3):657–663CrossRefPubMed
44.
Zurück zum Zitat Trecarichi EM, Tumbarello M, Caira M, Candoni A, Cattaneo C, Pastore D, Fanci R, Nosari A, Vianelli N, Busca A, Spadea A, Pagano L (2011) Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies. Haematologica 96(1):e1–e3CrossRefPubMed Trecarichi EM, Tumbarello M, Caira M, Candoni A, Cattaneo C, Pastore D, Fanci R, Nosari A, Vianelli N, Busca A, Spadea A, Pagano L (2011) Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies. Haematologica 96(1):e1–e3CrossRefPubMed
45.
Zurück zum Zitat Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, Ferrant A, Rapoport B, Rolston K, Paesmans M (2007) Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents S1:S51–S59CrossRef Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, Ferrant A, Rapoport B, Rolston K, Paesmans M (2007) Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents S1:S51–S59CrossRef
46.
Zurück zum Zitat Cruciani M, Rampazzo R, Malena M, Lazzarini L, Todeschini G, Messori A, Concia E (1996) Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 23:795–805CrossRefPubMed Cruciani M, Rampazzo R, Malena M, Lazzarini L, Todeschini G, Messori A, Concia E (1996) Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 23:795–805CrossRefPubMed
47.
Zurück zum Zitat Bow EJ (2011) Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients. Curr Opin Infect Dis 24(6):545–553CrossRefPubMed Bow EJ (2011) Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients. Curr Opin Infect Dis 24(6):545–553CrossRefPubMed
48.
Zurück zum Zitat CLSI (2008) Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. CLSI document M100-S18. Enterobacteriaceae M7MIC. Clinical and Laboratory Standards Institute, Wayne, PA, pp 98–101 CLSI (2008) Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. CLSI document M100-S18. Enterobacteriaceae M7MIC. Clinical and Laboratory Standards Institute, Wayne, PA, pp 98–101
49.
Zurück zum Zitat Saito T, Yoshioka S, Iinuma Y, Takakura S, Fujihara N, Ichinohe T, Ishikawa T, Uchiyama T, Ichiyama S (2008) Effects on spectrum and susceptibility patterns of isolates causing bloodstream infection by restriction of fluoroquinolone prophylaxis in a hematology–oncology unit. Eur J Clin Microbiol Infect Dis 27:209–216CrossRefPubMed Saito T, Yoshioka S, Iinuma Y, Takakura S, Fujihara N, Ichinohe T, Ishikawa T, Uchiyama T, Ichiyama S (2008) Effects on spectrum and susceptibility patterns of isolates causing bloodstream infection by restriction of fluoroquinolone prophylaxis in a hematology–oncology unit. Eur J Clin Microbiol Infect Dis 27:209–216CrossRefPubMed
50.
Zurück zum Zitat Engels EA, Ellis CA, Supran SE, Schmid CH, Barza M, Schenkein DP, Koc Y, Miller KB, Wong JB (1999) Early infection in bone marrow transplantation: quantitative study of clinical factors that affect risk. Clin Infect Dis 28:256–266CrossRefPubMed Engels EA, Ellis CA, Supran SE, Schmid CH, Barza M, Schenkein DP, Koc Y, Miller KB, Wong JB (1999) Early infection in bone marrow transplantation: quantitative study of clinical factors that affect risk. Clin Infect Dis 28:256–266CrossRefPubMed
51.
Zurück zum Zitat Ghosh I, Raina V, Kumar L, Sharma A, Bakhshi S, Thulkar S, Kapil A (2012) Profile of infections and outcome in high-risk febrile neutropenia: experience from a tertiary care cancer center in India. Med Oncol 29(2):1354–1360CrossRefPubMed Ghosh I, Raina V, Kumar L, Sharma A, Bakhshi S, Thulkar S, Kapil A (2012) Profile of infections and outcome in high-risk febrile neutropenia: experience from a tertiary care cancer center in India. Med Oncol 29(2):1354–1360CrossRefPubMed
52.
Zurück zum Zitat Richard P, Delangi MH, Raffi F, Espaze E, Richet H (2001) Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant, gram-negative bacilli from gastrointestinal flora. Clin Infect Dis 32:162–166CrossRefPubMed Richard P, Delangi MH, Raffi F, Espaze E, Richet H (2001) Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant, gram-negative bacilli from gastrointestinal flora. Clin Infect Dis 32:162–166CrossRefPubMed
53.
Zurück zum Zitat Cheong HJ, Yoo CW, Sohn JW, Kim WJ, Kim MJ, Park SC (2001) Bacteremia due to quinolone-resistant Escherichia coli in a teaching hospital in South Korea. Clin Infect Dis 33:48–53CrossRefPubMed Cheong HJ, Yoo CW, Sohn JW, Kim WJ, Kim MJ, Park SC (2001) Bacteremia due to quinolone-resistant Escherichia coli in a teaching hospital in South Korea. Clin Infect Dis 33:48–53CrossRefPubMed
54.
Zurück zum Zitat McDonald LC, Chen FJ, Lo HJ, Yin HC, Lu PL, Huang CH, Chen P, Lauderdale TL, Ho M (2001) Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressures. Antimicrob Agents Chemother 45:3084–3089CrossRefPubMed McDonald LC, Chen FJ, Lo HJ, Yin HC, Lu PL, Huang CH, Chen P, Lauderdale TL, Ho M (2001) Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressures. Antimicrob Agents Chemother 45:3084–3089CrossRefPubMed
55.
Zurück zum Zitat Lodise TP Jr, Patel N, Kwa A, Graves J, Furuno JP, Graffunder E, Lomaestro B, McGregor JC (2007) Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 51(10):3510–3515CrossRefPubMed Lodise TP Jr, Patel N, Kwa A, Graves J, Furuno JP, Graffunder E, Lomaestro B, McGregor JC (2007) Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 51(10):3510–3515CrossRefPubMed
56.
Zurück zum Zitat Giske CG, Monnet DL, Cars O, Carmeli Y, ReAct-Action on Antibiotic Resistance (2008) Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 52(3):813–821CrossRefPubMed Giske CG, Monnet DL, Cars O, Carmeli Y, ReAct-Action on Antibiotic Resistance (2008) Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 52(3):813–821CrossRefPubMed
57.
Zurück zum Zitat Caselli D, Cesaro S, Ziino O, Zanazzo G, Manicone R, Livadiotti S, Cellini M, Frenos S, Milano GM, Cappelli B, Licciardello M, Beretta C, Aricò M, Castagnola E, Infection Study Group of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) (2010) Multidrug resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation. Haematologica 95(9):1612–1615CrossRefPubMed Caselli D, Cesaro S, Ziino O, Zanazzo G, Manicone R, Livadiotti S, Cellini M, Frenos S, Milano GM, Cappelli B, Licciardello M, Beretta C, Aricò M, Castagnola E, Infection Study Group of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) (2010) Multidrug resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation. Haematologica 95(9):1612–1615CrossRefPubMed
Metadaten
Titel
Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance
verfasst von
E. Montassier
E. Batard
T. Gastinne
G. Potel
M. F. de La Cochetière
Publikationsdatum
01.07.2013
Verlag
Springer-Verlag
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 7/2013
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-013-1819-7

Weitere Artikel der Ausgabe 7/2013

European Journal of Clinical Microbiology & Infectious Diseases 7/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.